-
Je něco špatně v tomto záznamu ?
The Prevalence of the Thrombotic SNPs rs6025, rs1799963, rs2066865, rs2289252 and rs8176719 in Patients with Venous Thromboembolism in the Czech Population
T. Kvasnicka, R. Cifkova, Z. Zenahlikova, P. Bobcikova, A. Syruckova, M. Sevcik, D. Dusková, J. Kvasnicka
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2019
PubMed Central
od 2018
Europe PubMed Central
od 2018
ProQuest Central
od 1995-01-01
Medline Complete (EBSCOhost)
od 2006-07-01
Health & Medicine (ProQuest)
od 1995-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1995
- MeSH
- ABO systém krevních skupin genetika MeSH
- dospělí MeSH
- faktor V * genetika MeSH
- fibrinogen * genetika MeSH
- genetická predispozice k nemoci MeSH
- jednonukleotidový polymorfismus * MeSH
- lidé středního věku MeSH
- lidé MeSH
- prevalence MeSH
- protrombin genetika MeSH
- senioři MeSH
- žilní tromboembolie * genetika epidemiologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
IntroductionStudy aimed to determine the occurrence of 5 thrombosis-related single-nucleotide polymorphisms (SNPs) in patients with venous thromboembolism (VTE) (n = 2630) and a control group (n = 2637) in the Czech population.MethodsThe following gene SNPs were detected in both groups: F5 Leiden (rs6025), F2 (rs1799963), FGG, fibrinogen gamma' (rs2066865), F11 (rs2289252) and ABO (rs8176719). Statistical analysis was performed using SAS statistical software with population genetics tools.ResultsHeterozygotes for F5 Leiden were associated with a 5.58-fold and homozygotes F5 Leiden with a 33.46-fold increased risk of VTE. At SNP rs1799963 (F2, prothrombin), only heterozygotes had a significant 3.9-fold increased risk of VTE. The findings at SNP rs2066865 (fibrinogen gamma', FGG) showed a 1.37-fold increased risk of VTE for FGG heterozygotes and a 1.77-fold increased risk of VTE for FGG homozygotes. There is also a significant 1.42-fold increase risk of VTE in the heterozygotes and a 1.80-fold increase risk of VTE in the homozygotes of the SNP rs 2289252 (F11). Further higher increases in the risk of VTE in both variants were found in patients with VTE at rs8176719 (ABO, non-O). It corresponds to a 2.2-fold increase in the risk of VTE in heterozygotes and a 3.5-fold increase in the risk of VTE in homozygotes.ConclusionBesides F5 Leiden and prothrombin mutation, the study suggests that the gene polymorphisms of FGG (rs2066865), F11 (rs2289252) and ABO (rs8176719) play a role as an independent heritable risk factor for VTE in the Czech population.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010364
- 003
- CZ-PrNML
- 005
- 20250429134537.0
- 007
- ta
- 008
- 250415e20250317xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/10760296251324202 $2 doi
- 035 __
- $a (PubMed)40094632
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kvasnicka, Tomas $u Thrombotic Centre, Institute of Medical Biochemistry and Laboratory Diagnostics, first Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000195463750 $7 xx0061420
- 245 14
- $a The Prevalence of the Thrombotic SNPs rs6025, rs1799963, rs2066865, rs2289252 and rs8176719 in Patients with Venous Thromboembolism in the Czech Population / $c T. Kvasnicka, R. Cifkova, Z. Zenahlikova, P. Bobcikova, A. Syruckova, M. Sevcik, D. Dusková, J. Kvasnicka
- 520 9_
- $a IntroductionStudy aimed to determine the occurrence of 5 thrombosis-related single-nucleotide polymorphisms (SNPs) in patients with venous thromboembolism (VTE) (n = 2630) and a control group (n = 2637) in the Czech population.MethodsThe following gene SNPs were detected in both groups: F5 Leiden (rs6025), F2 (rs1799963), FGG, fibrinogen gamma' (rs2066865), F11 (rs2289252) and ABO (rs8176719). Statistical analysis was performed using SAS statistical software with population genetics tools.ResultsHeterozygotes for F5 Leiden were associated with a 5.58-fold and homozygotes F5 Leiden with a 33.46-fold increased risk of VTE. At SNP rs1799963 (F2, prothrombin), only heterozygotes had a significant 3.9-fold increased risk of VTE. The findings at SNP rs2066865 (fibrinogen gamma', FGG) showed a 1.37-fold increased risk of VTE for FGG heterozygotes and a 1.77-fold increased risk of VTE for FGG homozygotes. There is also a significant 1.42-fold increase risk of VTE in the heterozygotes and a 1.80-fold increase risk of VTE in the homozygotes of the SNP rs 2289252 (F11). Further higher increases in the risk of VTE in both variants were found in patients with VTE at rs8176719 (ABO, non-O). It corresponds to a 2.2-fold increase in the risk of VTE in heterozygotes and a 3.5-fold increase in the risk of VTE in homozygotes.ConclusionBesides F5 Leiden and prothrombin mutation, the study suggests that the gene polymorphisms of FGG (rs2066865), F11 (rs2289252) and ABO (rs8176719) play a role as an independent heritable risk factor for VTE in the Czech population.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a jednonukleotidový polymorfismus $7 D020641
- 650 12
- $a žilní tromboembolie $x genetika $x epidemiologie $7 D054556
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a faktor V $x genetika $7 D005165
- 650 12
- $a fibrinogen $x genetika $7 D005340
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a ABO systém krevních skupin $x genetika $7 D000017
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protrombin $x genetika $7 D011516
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Cifkova, Renata $u Center for Cardiovascular Prevention, first Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
- 700 1_
- $a Zenahlikova, Zuzana $u Thrombotic Centre, Institute of Medical Biochemistry and Laboratory Diagnostics, first Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Bobcikova, Petra $u Thrombotic Centre, Institute of Medical Biochemistry and Laboratory Diagnostics, first Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Syruckova, Alena $u Thrombotic Centre, Institute of Medical Biochemistry and Laboratory Diagnostics, first Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Sevcik, Martin $u Thrombotic Centre, Institute of Medical Biochemistry and Laboratory Diagnostics, first Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Dusková, Daniela $u 1st Department of Medicine, Division of Hematology, first Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $u Department of Blood Transfusion, first Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Kvasnicka, Jan $u 1st Department of Medicine, Division of Hematology, first Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00001108 $t Clinical and applied thrombosis/hemostasis $x 1938-2723 $g Roč. 31 (20250317), s. 10760296251324202
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40094632 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134532 $b ABA008
- 999 __
- $a ok $b bmc $g 2311614 $s 1247445
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 31 $c - $d 10760296251324202 $e 20250317 $i 1938-2723 $m Clinical and applied thrombosis/hemostasis $n Clin Appl Thromb Hemost $x MED00001108
- LZP __
- $a Pubmed-20250415
